

=> d his

(FILE 'HOME' ENTERED AT 14:43:04 ON 11 MAY 2004)

FILE 'REGISTRY' ENTERED AT 14:43:12 ON 11 MAY 2004




L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 3 S L1 OR L2
L4 105 S L3 FULL

FILE 'CAPLUS' ENTERED AT 14:44:49 ON 11 MAY 2004

L5 1 S L4

=> d que 15 stat

L1 STR





G1 O.S.N

G2 [01].[02]

Structure attributes must be viewed using STN Express query preparation.

L2 STR



G1 O.S.N
G2 [01].[02]
G3 C.N

Structure attributes must be viewed using STN Express query preparation.

L4 105 SEA FILE=REGISTRY SSS FUL L1 OR L2

L5 1 SEA FILE=CAPLUS ABB=ON PLU=ON L4

=> d bib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:252518 CAPLUS

DN 140:287398

TI Preparation of antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines as serotonin reuptake inhibitors and 5-HT1A receptor antagonists

IN Stack, Gary Paul; Webb, Michael Byron; Evrard, Deborah Ann; Zhou, Dahui

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024734	A1	20040325	WO 2003:US28524	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RD, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-410347P P 20020912

G1




L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676121-98-5 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676122-04-6 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The title compds. [I: Y = H, III: X = O, N-CH, CR7:CH, CR7:N (wherein R7 = H, alkyl); Z = O, S, NR8 (R8 = H, alkyl); R1, R5, R6 = H, OH, halo, CN, etc.; R2 = H, halo, NH2, mono- or dialkylamino, alkyl; R3, R4 = H, alkyl; n = 1-3], useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alc. addiction, sexual dysfunction and related illnesses, were prepared thus, reacting (2R)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-ylmethyl 4-bromobenzenesulfonate with 2-(5-methoxy-1H-indol-3-yl)ethylamine in DMSO afforded (2S)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-ylmethyl)amine. The exemplified compds. I were tested for 5-HT transporter affinity, 5-HT1A receptor affinity, and antagonistic activity at 5-HT1A receptors and biol. data were given. The pharmaceutical composition comprising the compound I is claimed.


IT 676121-84-9P 676121-98-5P 676122-04-6P
676122-06-8P 676122-08-0P 676122-20-6P
676122-26-2P 676122-32-0P 676122-36-4P
676122-38-6P 676122-40-0P 676122-46-6P
676122-49-9P 676122-53-5P 676122-55-7P
676122-57-9P 676122-65-9P 676123-00-5P
RL: PAC (Pharmacological activity): RCT (Reactant): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): RACT (Reactant or reagent): USES (Uses)
(preparation of antidepressant indolealkyl derivs. of (dioxinoquinolinylmethyl)amines as serotonin reuptake inhibitors and 5-HT1A receptor antagonists)

RN 676121-84-9 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-06-8 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676122-08-0 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-20-6 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-(3-benzothien-3-yl)propyl-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-26-2 CAPLUS
 CN [1,4]Dioxino[2,3-g]benzoxazole-8-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-7,8-dihydro-2-methyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-32-0 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-36-4 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(3-benzofuranyl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-38-6 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-40-0 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[3-[[[(8S)-7,8-dihydro-2-methyl[1,4]dioxino[2,3-g]benzoxazol-8-yl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-46-6 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(6-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-49-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1-methyl-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-53-5 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]propyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-55-7 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(6-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676123-00-5 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(4-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 676121-80-5P 676121-81-6P 676121-82-7P
 676121-83-8P 676121-85-0P 676121-86-1P
 676121-87-2P 676121-88-3P 676121-89-4P
 676121-90-7P 676121-91-8P 676121-92-9P
 676121-93-0P 676121-94-1P 676121-95-2P
 676121-96-3P 676121-97-4P 676121-99-6P
 676122-00-2P 676122-01-3P 676122-02-4P
 676122-03-5P 676122-05-7P 676122-07-9P
 676122-09-1P 676122-10-4P 676122-11-5P
 676122-12-6P 676122-13-7P 676122-14-8P
 676122-15-9P 676122-16-0P 676122-17-1P
 676122-18-2P 676122-19-3P 676122-21-7P
 676122-22-8P 676122-23-9P 676122-24-0P
 676122-25-1P 676122-27-3P 676122-28-4P

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-57-9 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[4-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676122-65-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


676122-29-5P 676122-30-8P 676122-31-9P
 676122-33-1P 676122-34-2P 676122-35-3P
 676122-37-5P 676122-39-7P 676122-41-1P
 676122-42-2P 676122-43-3P 676122-44-4P
 676122-45-5P 676122-47-7P 676122-48-8P
 676122-50-2P 676122-51-3P 676122-52-4P
 676122-54-6P 676122-56-8P 676122-58-0P
 676122-59-1P 676122-60-4P 676122-61-5P
 676122-62-6P 676122-63-7P 676122-64-8P
 676122-66-0P 676122-67-1P 676122-68-2P
 676122-69-3P 676122-70-6P 676122-71-7P
 676122-72-8P 676122-73-9P 676122-74-0P
 676122-75-1P 676122-76-2P 676122-77-3P
 676122-78-4P 676122-79-5P 676122-81-9P
 676123-04-9P 676123-05-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIDL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antidepressant indolealkyl derivs. of (dioxinoquinolinyl)methylamines as serotonin reuptake inhibitors and 5-HT1A receptor antagonists)

RN 676121-80-5 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676121-81-6 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-8-methyl-, (2S)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CRN 676121-80-5
 CMF C24 H25 N3 O3

Absolute stereochemistry.



CH 2

CRN 144-62-7
 CMF C2 H2 O4



RN 676121-82-7 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[2-(5-chloro-1H-indol-3-yl)ethyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CH 2

CRN 144-62-7
 CMF C2 H2 O4




RN 676121-85-0 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 676121-84-9
 CMF C24 H24 F N3 O2


Absolute stereochemistry.



CH 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 676121-86-1 CAPLUS

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676121-83-8 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[2-(5-chloro-1H-indol-3-yl)ethyl]-2,3-dihydro-8-methyl-, (2S)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 676121-82-7
 CMF C23 H22 Cl N3 O2

Absolute stereochemistry.



L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676121-87-2 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-2,3-dihydro-8-methyl-, (2S)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 676121-86-1
 CMF C23 H22 F N3 O2

Absolute stereochemistry.




L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 676121-88-3 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 8-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676121-89-4 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 8-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-, (2S)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676121-88-3
CMF C25 H26 F N3 O2

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 676121-91-8 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[3-(1H-indol-3-yl)propyl]-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676121-90-7
CMF C24 H25 N3 O2


Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 676121-92-9 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 676121-90-7 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[3-(1H-indol-3-yl)propyl]-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676121-93-0 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676121-92-9
CMF C25 H26 F N3 O2

Absolute stereochemistry.




CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676121-94-1 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(7-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676121-95-2 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(7-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 676121-94-1

CHF C24 H24 F N3 O2

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CH 2

CRN 110-17-8

CHF C4 H4 O4

Double bond geometry as shown.




RN 676121-96-3 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[4-(1H-indol-3-yl)butyl]-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676121-97-4 CAPLUS


CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[4-(1H-indol-3-yl)butyl]-8-methyl-, (2S)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CH 1

CRN 676121-96-3

CHF C25 H27 N3 O2

Absolute stereochemistry.




CH 2

CRN 110-17-8

CHF C4 H4 O4

Double bond geometry as shown.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676121-99-6 CAPLUS


CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 676121-98-5

CHF C25 H26 F N3 O2

Absolute stereochemistry.




CH 2

CRN 110-17-8

CHF C4 H4 O4

Double bond geometry as shown.




RN 676122-00-2 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[(1R)-3-(5-fluoro-1H-indol-3-yl)-1-methylpropyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676122-01-3 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[(1R)-3-(5-fluoro-1H-indol-3-yl)-1-methylpropyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 676122-00-2
 CMF C25 H26 F N3 O2


Absolute stereochemistry.



CM 2

CRN 110-17-8


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 676122-05-7 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[(1R)-3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1


CRN 676122-04-6
 CMF C25 H26 F N3 O2

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CMF C4 H4 O4

Double bond geometry as shown.



RN 676122-02-4 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[(1S)-3-(5-fluoro-1H-indol-3-yl)-1-methylpropyl]-2,3-dihydro-8-methyl-, (2S)-, (9C1) (CA INDEX NAME)

Absolute stereochemistry.




RN 676122-03-5 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[(1S)-3-(5-fluoro-1H-indol-3-yl)-1-methylpropyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 676122-02-4
 CMF C25 H26 F N3 O2

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 676122-07-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[(1S)-3-(5,7-difluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 676122-06-8
 CMF C24 H23 F2 N3 O2

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 676122-09-1 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-, dihydrochloride. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl


RN 676122-10-4 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 676122-11-5 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N-methyl-, dihydrochloride. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl


RN 676122-12-6 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 676122-13-7 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, dihydrochloride. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-14-8 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[2-(3-benzofuranyl)ethyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 676122-15-9 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[2-(3-benzofuranyl)ethyl]-2,3-dihydro-8-methyl-, (2S)- (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 676122-14-8
CMF C23 H22 N2 O3

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 676122-16-0 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(3-benzofuranyl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CMF C4 H4 O4


Double bond geometry as shown.



RN 676122-18-2 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[3-(7-methoxy-3-benzofuranyl)propyl]-8-methyl-, (2S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



RN 676122-19-3 CAPLUS


CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, 2,3-dihydro-N-[3-(7-methoxy-3-benzofuranyl)propyl]-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 676122-18-2
CMF C25 H26 N2 O4

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676122-17-1 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(3-benzofuranyl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 676122-16-0
CMF C24 H24 N2 O3


Absolute stereochemistry.



CM 2

CRN 110-17-8


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 676122-21-7 CAPLUS


CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-(3-benzo[b]thien-3-ylpropyl)-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 676122-20-6
CMF C24 H24 N2 O2 S

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CH 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 676122-22-8 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-(2-benzo[b]thien-3-ylethyl)-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CH 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 676122-24-0 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-(3-benzo[b]thien-3-ylpropyl)-2,3-dihydro-N,8-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676122-25-1 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-(3-benzo[b]thien-3-ylpropyl)-2,3-dihydro-N,8-dimethyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 676122-24-0
CMF C25 H26 N2 O2 S

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676122-23-9 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-(2-benzo[b]thien-3-ylethyl)-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 676122-22-8
CMF C23 H22 N2 O2 S

Absolute stereochemistry.




L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CH 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 676122-27-3 CAPLUS
CN [1,4]dioxino[2,3-g]benzoxazole-8-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-7,8-dihydro-2-methyl-, hydrochloride (2:3), (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●3/2 HCl

RN 676122-28-4 CAPLUS
 CN [1,4]Dioxino[2,3-g]benzoxazole-8-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-7,8-dihydro-N,2-dimethyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-29-5 CAPLUS
 CN [1,4]Dioxino[2,3-g]benzoxazole-8-methanamine, N-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, dihydrochloride, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-33-1 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 676122-34-2 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-30-8 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-31-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-35-3 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5,7-difluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl


RN 676122-37-5 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(3-benzofuranyl)butyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (5:4) (9CI) (CA INDEX NAME)

CM 1

CRN 676122-36-4
 CHF C25 H26 N2 O3

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8
CHF C4 H4 O4

Double bond geometry as shown.




RN 676122-39-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]propyl]-, dihydrochloride (9C1) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 676122-43-3 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[3-[[[(8S)-7,8-dihydro-2-methyl[1,4]dioxino[2,3-g]benzoxazol-8-yl]methyl]methylamino]propyl]-, dihydrochloride (2:3) (9C1) (CA INDEX NAME)

Absolute stereochemistry.




●3/2 HCl

RN 676122-44-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]methylamino]propyl]-, dihydrochloride (2:3) (9C1) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-41-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[3-[[[(8S)-7,8-dihydro-2-methyl[1,4]dioxino[2,3-g]benzoxazol-8-yl]methyl]amino]propyl]-, dihydrochloride (2:3) (9C1) (CA INDEX NAME)


Absolute stereochemistry.



●3/2 HCl


RN 676122-42-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[3-[[[(8S)-7,8-dihydro-2-methyl[1,4]dioxino[2,3-g]benzoxazol-8-yl]methyl]methylamino]propyl]-, dihydrochloride (2:3) (9C1) (CA INDEX NAME)

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-45-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]methylamino]propyl]-, dihydrochloride (2:3) (9C1) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 676122-47-7 CAPLUS
CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(6-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, dihydrochloride, (2S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-48-8 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(6-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, trihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl

RN 676122-50-2 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1-methyl-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-54-6 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]propyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 676122-56-8 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(6-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 676122-51-3 CAPLUS
 CN [1,4]Dioxino[2,3-g]benzoxazole-8-methanamine, N-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-7,8-dihydro-2-methyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-52-4 CAPLUS
 CN [1,4]Dioxino[2,3-g]benzoxazole-8-methanamine, N-ethyl-N-[3-(5-fluoro-1H-indol-3-yl)propyl]-7,8-dihydro-2-methyl-, dihydrochloride, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 676122-58-0 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[4-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]butyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 676122-59-1 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl]methyl]amino]propyl]-1-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-60-4 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[3-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl)methyl]methylamino]propyl]-1-methyl-, dihydrochloride (9C1) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-61-5 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[4-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl)methyl]methylamino]butyl]-1-methyl-, dihydrochloride (9C1) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-62-6 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[4-[[[(2S)-2,3-dihydro-8-methyl-1,4-dioxino[2,3-f]quinolin-2-yl)methyl]methylamino]butyl]-1-methyl-, dihydrochloride (9C1) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-63-7 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, (2S)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-64-8 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1-methyl-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, dihydrochloride, (2S)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-66-0 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1-methyl-1H-indol-3-yl)butyl]-2,3-dihydro-N,8-dimethyl-, dihydrochloride, (2S)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-67-1 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1-methyl-1H-indol-3-yl)butyl]-2,3-dihydro-N,8-dimethyl-, (2S)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-68-2 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-fluoro-1-methyl-1H-indol-3-yl)butyl]-2,3-dihydro-N,8-dimethyl-, dihydrochloride, (2S)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-69-3 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-N-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676122-70-6 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-N-propyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 676122-73-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(4-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676122-74-0 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-chlorobenzo[b]thien-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-71-7 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(4-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-8-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676122-72-8 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(6-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-N,8-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 676122-75-1 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(5-chlorobenzo[b]thien-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676122-74-0
 CMF C25 H25 Cl N2 O2 S

Absolute stereochemistry.




CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676122-76-2 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-chlorobenzo[b]thien-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676122-77-3 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-chlorobenzo[b]thien-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676122-76-2
 CMF C24 H23 Cl N2 O2 S

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 676122-78-4 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluorobenzo[b]thien-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676122-79-5 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(5-fluorobenzo[b]thien-3-yl)propyl]-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676122-78-4
 CMF C24 H23 F N2 O2 S

Absolute stereochemistry.




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 676122-81-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(3-benzofuranyl)butyl]-N-ethyl-2,3-dihydro-8-methyl-, (2S)-, (2E)-2-butenedioate (10:13) (9CI) (CA INDEX NAME)

CM 1

CRN 676122-80-8
 CMF C27 H30 N2 O3


Absolute stereochemistry.



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 676123-04-9 CAPLUS
 CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[3-(6-fluoro-1H-indol-3-yl)propyl]-2,3-dihydro-N,8-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676123-05-0 CAPLUS

CN 1,4-Dioxino[2,3-f]quinoline-2-methanamine, N-[4-(6-fluoro-1H-indol-3-yl)butyl]-2,3-dihydro-8-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d que l11 stat

L6	72	SEA FILE=CAPLUS	ABB=ON	PLU=ON	("STACK GARY P"/AU OR "STACK GARY PAUL"/AU)
L7	8	SEA FILE=CAPLUS	ABB=ON	PLU=ON	"WEBB MICHAEL BYRON"/AU
L8	26	SEA FILE=CAPLUS	ABB=ON	PLU=ON	("EVRARD DEBORAH A"/AU OR "EVRARD DEBORAH ANN"/AU)
L9	22	SEA FILE=CAPLUS	ABB=ON	PLU=ON	"ZHOU DAHUI"/AU
L10	116	SEA FILE=CAPLUS	ABB=ON	PLU=ON	L6 OR L7 OR L8 OR L9
L11	12	SEA FILE=CAPLUS	ABB=ON	PLU=ON	L10 AND BENZODIOXAN

=> d 1-12 bib abs hitstr

L11 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:252518 CAPLUS

DN 140:287398

TI Preparation of antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines as serotonin reuptake inhibitors and 5-HT1A receptor antagonists

IN Stack, Gary Paul; Webb, Michael Byron; Evrard,

Deborah Ann; Zhou, Dahui

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024734	A1	20040325	WO 2003-US28524	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRA1 US 2002-410347P P 20020912

GI



L11 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:252517 CAPLUS

DN 140:287397

TI Preparation of piperidine derivatives of heterocycle-fused benzodioxans as serotonin reuptake inhibitors and 5-HT1A receptors antagonists for treating depression

IN Webb, Michael Byron; Stack, Gary Paul; Asselin, Magda;

Evrard, Deborah Ann

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024733	A1	20040325	WO 2003-US28523	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRA1 US 2002-410033P P 20020912

GI



AB The title compds. (shown as I: variables defined below: e.g. II), useful for the treatment of depression (including but not limited to major

L11 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The title compds. [I: Y = II, III: X = O, N; CH, CR7:CH, CR7:N (wherein R7 = H, alkyl); Z = O, S, NR8 (R8 = H, alkyl); R1, R5, R6 = H, OH, halo, CN, etc.; R2 = H, halo, NH2, mono- or dialkylamino, alkyl; R3, R4 = H, alkyl; n = 1-3], useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alc. addiction, sexual dysfunction and related illnesses, were prepared. Thus, reacting (2R)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-ylmethyl 4-bromobenzenesulfonate with 2-(5-methoxy-1H-indol-3-yl)ethylamine in DMSO afforded (2S)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-ylmethyl)amine. The exemplified compds. I were tested for 5-HT transporter affinity, 5-HT1A receptor affinity, and antagonistic activity at 5-HT1A receptors and biol. data were given. The pharmaceutical composition comprising the compound I is claimed.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alc. addiction, sexual dysfunction and related illnesses, were prepd. For I: R1, R2 and R3 = H, OH, halo, CN, carboxamido, carboxalkoxy, CF3, alkyl, alkoxy, alkanoyl, alkanoyloxy, NH2, mono- or dialkylamino, alkanamido, alkanesulfonyl or alkanesulfonamido; X, Y = H, OH, halo, CN, carboxamido, carboxalkoxy, CF3, alkyl, alkoxy, alkanoyl, alkanoyloxy, amino, mono- or dialkylamino, alkanamido, alkanesulfonyl or alkanesulfonamido, or X and Y, taken together, form -N:C(R4)-C(R5)-N-, -N:C(R4)-C(R6)-CH-, -N:C(R4)-N:CH-, -N:C(R4)-O-, -NH-C(R7)-N- or -NH-C(R8)-CH-; R4 and R5 = H, halo, amino, mono- or dialkylamino; R6 = H, alkyl; R7 = H, halo, CF3, pentafluoroethyl, amino, mono- or dialkylamino; R8 = H, halo, CF3, pentafluoroethyl, alkyl; the dotted line = an optional double bond; Z = O, S; Q = C, N; n = 0-1; addnl. details are given in the claims. Although the methods of prepn. are not claimed, 14 example preps. are included. For example, II was prepd. by reacting [(2R)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl 4-toluenesulfonate with 4-(benzo[b]thiophen-3-yl)-1,2,3,6-tetrahydropyridine in DMSO. The compds. I were tested for serotonin transporter affinity, 5-HT1A receptor affinity, and antagonistic activity at 5-HT1A receptors, and biol. data were given for all exemplified compds. The pharmaceutical compn. comprising the compd. I is claimed.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2004:252516 CAPLUS

DN 140:287396

TI Preparation of antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans

IN Stack, Gary Paul; Evrard, Deborah Ann; Shah, Uresh Shantila

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024732	A1	20040325	WO 2003-US28459	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRA1 US 2002-410072P	P	20020912		
US 2003-659174	A	20030910		

G1



L11 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2004:252515 CAPLUS

DN 140:287410

TI Preparation of antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans

IN Evrard, Deborah A.; Zhou, Dahui; Stack, Gary Paul; Venkatesan, Arenapam Madumbai; Failli, Amedeo A.; Croce, Susan Christman

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024731	A1	20040325	WO 2003-US28453	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRA1 US 2002-410082P	P	20020912		
US 2003-659537	A	20030910		

G1



AB The title compds. [R1 = H, halo, CN, carboxamido, etc.; XY = N-CR2CR3:N, N-CR2CR4:CH, N-CR2N:CH, N-CR2O, NHCR5:CH, R2, R3 = H, halo, NH2, mono- or dialkylamino, alkyl; R4 = H, alkyl; R5 = H, halo, CF3, pentafluoroethyl, alkyl; Ar = (un)substituted Ph, naphthyl, indolyl, indazolyl, thienyl, etc.; n = 1-2], useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor

L11 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

AB The title compds. [R1 = H, halo, CN, carboxamido, etc.; R2 = H, alkyl; XY = N-CR3CR4:N, NCR3CR5:CH, N-CR3N:CH, N-CR3O, NHCR6:N, NHCR7:CH; R3, R4 = H, halo, NH2, mono- or dialkylamino, alkyl; R5 = H, alkyl; R6 = H, halo, CF3, pentafluoroethyl, NH2, etc.; R7 = H, halo, CF3, pentafluoroethyl, alkyl; O = II-IV (wherein Z = NR12, S, O; R8-R11 = H, OH, halo, CN, etc.; R12 = H, alkyl); m = 1-3; n = 1-2; p = 0-3] and their pharmaceutically acceptable salts, useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alc. addiction, sexual dysfunction and related illnesses, were prepared. Thus, reacting toluene-4-sulfonic acid [(2R)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl ester with cis-3-(1H-indol-3-yl)cyclopentylamine in DMSO afforded 16% N-[(cis)-3-(1H-indol-3-yl)cyclopentyl]-N-[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methylamine. The exemplified compds. I were tested for 5-HT transporter affinity, 5-HT1A receptor affinity, and antagonistic activity at 5-HT1A receptors and biol. data were given. The pharmaceutical composition comprising the compound I is claimed.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

flushing, cocaine and alc. addiction, sexual dysfunction and related illnesses, were prepd. Thus, reacting [(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl 4-bromobenzenesulfonate with 3-chlorophenylpiperazine.HCl in the presence of EtN(iso-Pr)2 in DMSO afforded 68% (2S)-2-[(4-(3-chlorophenyl)piperazin-1-yl)methyl]-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline. The exemplified compds. I were tested for 5-HT transporter affinity, 5-HT1A receptor affinity, and antagonistic activity at 5-HT1A receptors and biol. data were given. The pharmaceutical compn. comprising the compd. I is claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2004:252514 CAPLUS

DN 140:287395

T1 Preparation of antidepressant azaheterocyclimethyl derivs. of heterocycle-fused benzodioxans

IN Zhou, Dahui; Stack, Gary Paul

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024730	A1	20040325	WO 2003-US28413	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2002-410168P	P	20020912		
US 2003-659167	A	20030910		

GI



AB The title compds. [I: Q = II, III: R1-R3 = H, OH, halo, CN, carboxamido, etc.; X, Y = H, OH, halo, CN, etc.; or X and Y, taken together, form

L11 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

N:CRACRS:N, N:CRACRS:CH, N:CRAN:CH, N:CR4O, NHCR7:N, NHCR8:CH; R4, R5 = H, halo, NH2, mono- or dialkylamino, alkyl; R6 = H, alkyl; R7 = H, halo, CF3, etc.; R8 = H, halo, CF3, etc.; Z = O, S, NR9; R9 = H, alkyl; n = 0-2; m = 1-4 (with provisos); p = 1-3 (p+n = 2-3)], useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alc. addiction, sexual dysfunction and related illnesses, were prepd. Thus, reacting 4-bromobenzenesulfonic acid (2R)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-ylmethyl ester with 3-azetidin-3-ylmethyl-5-fluoro-1H-indole in the presence of Et3N in DMSO afforded (2S)-2-[3-(5-fluoro-1H-indol-3-ylmethyl)azetidin-1-ylmethyl]-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline. The exemplified compds. I were tested for 5-HT transporter affinity, 5-HT1A receptor affinity, and antagonistic activity at 5-HT1A receptors and biol. data were given. The pharmaceutical compn. comprising the compd. I is claimed.

RE, CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2003:678510 CAPLUS

DN 139:214473

T1 Preparation of antidepressant azaheterocyclimethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans

IN Stack, Gary P.; Gao, Hong; Gildersleeve, Elizabeth S.

PA Wyeth, John, and Brother Ltd., USA

SO U.S. Pat. Appl., Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 131,340.

CODEN: USXXCO

DT Patent


LA English

FAN, CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003162805	A1	20030828	US 2003-377901	20030303
US 6706736	B2	20040316		
US 2002183353	A1	20021205	US 2002-131340	20020424
US 6552049	B2	20030422		
PRAI US 2001-286569P	P	20010426		
US 2002-131340	A2	20020424		

OS MARPAT 139:214473

GI



AB The title compds. [I: R1, R3-R5, R7 = H, halo, CN, etc.; Y = CO, C(R2)2 and Z = CH2, (CH2)2, CH:CH, NR2; or Y and Z, taken together, form CR2:CH, N:CR2, CR2:N; R2, R6 = H, alkyl; X = CR7, N; n = 0-2], useful for the treatment of depression such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses, were prepared. E.g., a 5-step synthesis of (S)-II, starting from (2S)-(7-hydroxy-2,3-dihydro-1,4-

L11 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
benzodioxin-2-yl)methanol and 2,3-dichloro-1-propene, which showed Ki of 14.07 nM against 5-HT1A receptor binding, was given.

L11 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:849646 CAPLUS

DN 137:353043

TI Preparation of azabicyclomethyl derivatives of 7,8-dihydro-1,6,9-trioxo-3-azacyclopenta[a]naphthalene as 5-HT1A antagonists

IN Stack, Gary Paul; Gilbert, Adam Matthew; Tran, Megan

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 43 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN_CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088145	A1	20021107	WO 2002-US13114	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TH, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2002183336	A1	20021205	US 2002-131917	20020425
PRAI US 2001-286818P	P	20010426		
OS MARPAT 137:353043				
GI				



AB Azabicyclomethyl derivs. of 7,8-dihydro-1,6,9-trioxo-3-azacyclopenta[a]naphthalene [1: wherein X-Y-Z = N:C(R2)-O, N:C(R2)-NH, NH-C(R2)-CH; R1 = H, halo, CN, carboxamido, carboalkoxy, CF3, etc.; R2 = H, halo, CF3, amino, mono- or dialkylamino, etc.; R3 = Ph, naphthyl, anthracyl, phenanthryl, pyridyl, pyrimidyl, etc.] were prepared for

L11 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

example, (8R)-2-methyl-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-ylmethyl 4-methylbenzenesulfonate (synthetic prep. given) was reacted with 3-phenyl-8-azabicyclo[3.2.1]octan-3-ol to give 8-[[2-methyl-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-yl]methyl]-3-phenyl-8-azabicyclo[3.2.1]octanol. The title compds. are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and are also useful for the treatment of disorders such as anxiety, aggression and stress, and for the control of various physiol. phenomena, such as eating disorders, disorders of thermoregulation, and sleep and sexual dysfunction.

RE_CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:849638 CAPLUS

DN 137:353038

TI Preparation of antidepressant azaheterocyclomethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans

IN Stack, Gary Paul; Gao, Hong; Gildersleeve, Elizabeth Suzanne

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 35 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN_CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088135	A1	20021107	WO 2002-US12831	20020424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TH, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 1381613	A1	20040121	EP 2002-728947	20020424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI US 2001-286569P	P	20010426		
WO 2002-US12831	W	20020424		
OS MARPAT 137:353038				
GI				



AB The title compds. [1: R1, R3-R5, R7 = H, halo, CN, etc.; Y = CO, C(R2)2

L11 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

and Z = CH2, (CH2)2, CH, CH, NR2; or Y and Z, taken together, form CR2=CH, N:CR2, CR2=N; R2, R6 = H, alkyl; X = CR7, N; n = 0-2]. useful for the treatment of depression such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses, were prep'd. E.g., a 5-step synthesis of (S)-II, starting from (2S)-(7-hydroxy-2,3-dihydro-1,4-benzodioxin-2-yl)methanol and 2,3-dichloro-1-propene, which showed Ki of 14.07 nM against 5-HT1A receptor binding, was given.

RE_CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2002:832796 CAPLUS

DN 137:337897

TI Preparation of 8-aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan and their 5-HT1A antagonist activity

IN Gilbert, Adam Matthew; Stack, Gary Paul

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 34 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002085900	A1	20021031	WO 2002-US12837	20020424
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RD, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TZ, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2003032648	A1	20030213	US 2002-128057	20020423
US 6656951	B2	20031202		
US 2004063728	A1	20040401	US 2003-663533	20030916
PRAI US 2001-286061P	P	20010424		
US 2002-128057	A1	20020423		
OS MARPAT 137:337897				
GI				



L11 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 1992:571458 CAPLUS

DN 117:171458

TI Aminophenoxyalkyl derivatives of benzodioxan

IN Stack, Gary P.; Abou-Gharbia, Magid A.; Andree, Terrance H.; Scherer, Noreen T.

PA American Home Products Corp., USA

SO U.S., 10 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5126366	A	19920630	US 1991-719887	19910621
IL 102137	A1	19960723	IL 1992-102137	19920609
CZ 281049	B6	19960612	CZ 1992-1823	19920615
ZA 9204402	A	19931217	ZA 1992-4402	19920616
EP 520674	A1	19921230	EP 1992-305535	19920617
EP 520674	B1	19950816		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE			
JP 05194481	A2	19930803	JP 1992-157853	19920617
JP 3095533	B2	20001003		
ES 2076691	T3	19951101	ES 1992-305535	19920617
CA 2071669	AA	19921222	CA 1992-2071669	19920619
CA 2071669	C	20021029		
BR 9202321	A	19930119	BR 1992-2321	19920619
HU 61739	A2	19930301	HU 1992-2060	19920619
RU 2056417	C1	19960320	RU 1992-5011900	19920619
AU 9218426	A1	19921224	AU 1992-18426	19920622
AU 644743	B2	19931216		
PRAI US 1991-719882	A	19910621		
US 1991-719887	A	19910621		
OS MARPAT 117:171458				
GI				



AB The title compds. I [R = H, R1 = H, 6-, 7-HO, 5-, 7-, 8-MeO, 7-Cl, 7-F; R1 = 6,7-methylenedioxy; R = 6-MeO, R1 = 5-, 7-, 8-MeO] were prepared by alkylation of amines II with 3-DNCH4O(CH2)3X (X = Cl, Br) followed by

L11 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


AB The title compds. I (R1 = 1-6 carbon straight chain alkyl, 3-8 carbon branched alkyl, R2 = Ph, naphthyl, pyridyl, etc.) were prepared by reacting benzodioxans II (X = halogen, SO2CF3, alkylsulfonate, etc.) with the corresponding hydroxy azabicyclooctanol derivs. III. Thus, naphthalenylazabicyclooctanol IV was prepared from tropinone, 2-bromonaphthalene, and (R)-toluene-4-sulfonic acid 8-ethoxy-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl ester. In the HC 5-HT1A binding assay, IV had an activity of 5.9 nM Ki. I are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and also treatment of disorders related to excessive serotonergic stimulation, such as anxiety, aggression and stress, and for the control of various physiol. phenomena, such as appetite, thermoregulation, sleep and sexual behavior, which are known to be, at least in part, under serotonergic influence.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
hydrogenation of the NO2 group. I were antipsychotics, antidepressants and anxiolytics useful in the treatment of multi-CNS diseases.

L11 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:571457 CAPLUS
 DN 117:171457
 TI Psychotropic benzodioxan derivatives
 IN Stack, Gary P.; Abou-Gharbia, Magid A.; Childers, Wayne E., Jr.
 PA American Home Products Corp., USA
 SO U.S., 8 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5126367	A	19920630	US 1991-719881	19910621
PRAI	US 1991-719881		19910621		
OS	MARPAT 117:171457				
GI					



AB Title compds. I (R = adamantanecarbonyl, noradamantanecarbonyl, ketopinoyl, etc.) were prepared, by acylation of I (R = H) with agents such as adamantanecarbonyl chloride, etc. The title compds. were antipsychotics, antidepressants and anxiolytics useful in the treatment of multi-DNS diseases.

L11 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:532195 CAPLUS
 DN 113:132195
 TI Psychotropic benzodioxanyl polycyclic imides
 IN Abou-Gharbia, Magid A.; Stack, Gary P.
 PA American Home Products Corp., USA
 SO U.S., 6 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4910302	A	19900320	US 1988-286576	19881219
PRAI	US 1988-286576		19881219		
OS	CASREACT 113:132195; MARPAT 113:132195				
GI					



AB The title compds. [I: X = alkylene, ethynylene; O = alkylene, Q3, Q4, atoms to complete (substituted) benzene rings; Z = Q1, Q2, etc.; R4 = H, OH, CN, alkyl, alkoxy, amino; m = 2-5], were prepared thus. 2-chloromethylbenzodioxane and H2N(CH2)mNH2 were heated in N-methylpyrrolidinone at 100° for 24 h to give the benzodioxanylmethylaminobutylamine. The latter and decahydro-1,5-methano-6,8,9-methenopentaleno[1,2-d]oxepine-2,4(1H,5H)-dione were refluxed in xylene with removal of H2O to give decahydro-3-[4-[(2,3-dihydro-1,4-benzodioxan-2-ylmethylamino)butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-d]azepine-2,4(3H)-dione. The latter at 1 μM completely inhibited binding of 3H-spiroperidol to limbic brain tissue.